Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice

David Delotterie, Geoffrey Ruiz, Jacques Brocard, Annie Schweitzer, Corinne Roucard, Yann Roche, Marie Françoise Suaud-Chagny, Karine Bressand, Annie Andrieux

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Introduction: Recent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal proteins. The microtubule-associated protein stable tubule only polypeptide (STOP) plays a key role in neuronal architecture and synaptic plasticity, and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP null mice, behavioral defects are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and clozapine, two atypical antipsychotics, on STOP null mice behavior and synaptic plasticity. Results: Long-term administration of either drug results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects in STOP null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP null animals by restoring long-term potentiation in the hippocampus. Discussion: All together, the pharmacological reactivity of STOP null mice to antipsychotics evokes the pharmacological response of humans to such drugs. Totally, our study suggests that STOP null mice may provide a useful preclinical model to evaluate pharmacological properties of antipsychotic drugs.

Original languageEnglish (US)
Pages (from-to)131-141
Number of pages11
JournalPsychopharmacology
Volume208
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Antipsychotic Agents
Neuronal Plasticity
Peptides
Long-Term Potentiation
Clozapine
Pharmacology
Neurobehavioral Manifestations
Microtubule-Associated Proteins
Cytoskeletal Proteins
Risperidone
Gene Deletion
Pharmaceutical Preparations
Hippocampus
Schizophrenia
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. / Delotterie, David; Ruiz, Geoffrey; Brocard, Jacques; Schweitzer, Annie; Roucard, Corinne; Roche, Yann; Suaud-Chagny, Marie Françoise; Bressand, Karine; Andrieux, Annie.

In: Psychopharmacology, Vol. 208, No. 1, 01.01.2010, p. 131-141.

Research output: Contribution to journalArticle

Delotterie, D, Ruiz, G, Brocard, J, Schweitzer, A, Roucard, C, Roche, Y, Suaud-Chagny, MF, Bressand, K & Andrieux, A 2010, 'Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice', Psychopharmacology, vol. 208, no. 1, pp. 131-141. https://doi.org/10.1007/s00213-009-1712-3
Delotterie, David ; Ruiz, Geoffrey ; Brocard, Jacques ; Schweitzer, Annie ; Roucard, Corinne ; Roche, Yann ; Suaud-Chagny, Marie Françoise ; Bressand, Karine ; Andrieux, Annie. / Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. In: Psychopharmacology. 2010 ; Vol. 208, No. 1. pp. 131-141.
@article{5f048aa2eae04888bd1b2f430ebb18bf,
title = "Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice",
abstract = "Introduction: Recent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal proteins. The microtubule-associated protein stable tubule only polypeptide (STOP) plays a key role in neuronal architecture and synaptic plasticity, and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP null mice, behavioral defects are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and clozapine, two atypical antipsychotics, on STOP null mice behavior and synaptic plasticity. Results: Long-term administration of either drug results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects in STOP null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP null animals by restoring long-term potentiation in the hippocampus. Discussion: All together, the pharmacological reactivity of STOP null mice to antipsychotics evokes the pharmacological response of humans to such drugs. Totally, our study suggests that STOP null mice may provide a useful preclinical model to evaluate pharmacological properties of antipsychotic drugs.",
author = "David Delotterie and Geoffrey Ruiz and Jacques Brocard and Annie Schweitzer and Corinne Roucard and Yann Roche and Suaud-Chagny, {Marie Fran{\cc}oise} and Karine Bressand and Annie Andrieux",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s00213-009-1712-3",
language = "English (US)",
volume = "208",
pages = "131--141",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice

AU - Delotterie, David

AU - Ruiz, Geoffrey

AU - Brocard, Jacques

AU - Schweitzer, Annie

AU - Roucard, Corinne

AU - Roche, Yann

AU - Suaud-Chagny, Marie Françoise

AU - Bressand, Karine

AU - Andrieux, Annie

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction: Recent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal proteins. The microtubule-associated protein stable tubule only polypeptide (STOP) plays a key role in neuronal architecture and synaptic plasticity, and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP null mice, behavioral defects are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and clozapine, two atypical antipsychotics, on STOP null mice behavior and synaptic plasticity. Results: Long-term administration of either drug results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects in STOP null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP null animals by restoring long-term potentiation in the hippocampus. Discussion: All together, the pharmacological reactivity of STOP null mice to antipsychotics evokes the pharmacological response of humans to such drugs. Totally, our study suggests that STOP null mice may provide a useful preclinical model to evaluate pharmacological properties of antipsychotic drugs.

AB - Introduction: Recent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal proteins. The microtubule-associated protein stable tubule only polypeptide (STOP) plays a key role in neuronal architecture and synaptic plasticity, and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP null mice, behavioral defects are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and clozapine, two atypical antipsychotics, on STOP null mice behavior and synaptic plasticity. Results: Long-term administration of either drug results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects in STOP null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP null animals by restoring long-term potentiation in the hippocampus. Discussion: All together, the pharmacological reactivity of STOP null mice to antipsychotics evokes the pharmacological response of humans to such drugs. Totally, our study suggests that STOP null mice may provide a useful preclinical model to evaluate pharmacological properties of antipsychotic drugs.

UR - http://www.scopus.com/inward/record.url?scp=72649085418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72649085418&partnerID=8YFLogxK

U2 - 10.1007/s00213-009-1712-3

DO - 10.1007/s00213-009-1712-3

M3 - Article

VL - 208

SP - 131

EP - 141

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -